Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
55 hedge funds and large institutions have $10M invested in Oncternal Therapeutics, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 8 closing their positions.
5% less funds holding
Funds holding: 58 → 55 (-3)
11% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 18
13% less capital invested
Capital invested by funds: $11.5M → $10M (-$1.52M)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
51% less call options, than puts
Call options by funds: $139K | Put options by funds: $284K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$351K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$341K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$212K |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$172K |
| 5 |
ProShare Advisors
Bethesda,
Maryland
|
+$47.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$805K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$237K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$219K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$197K |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$100K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Wells Fargo
San Francisco,
California
| $5K | -$22.4K | -9 | -75% |
|
52
BNP Paribas Financial Markets
Paris,
France
| $3.15K | -$2.49K | -1 | -50% |
|
|
TCM
53
TD Capital Management
Memphis,
Tennessee
| $3K | – | – | – |
|
54
Barclays
London,
United Kingdom
| $2K | -$24.9K | -10 | -91% |
|
55
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $3 | -$14.9K | -6 | -86% |
|
|
TC
56
TFS Capital
West Chester,
Pennsylvania
| – | -$805K | -349 | Closed |
|
|
WMSA
57
Weiss Multi-Strategy Advisers
New York
| – | -$100K | -43 | Closed |
|
58
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$61K | -27 | Closed |
|
59
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$60K | -26 | Closed |
|
60
Renaissance Technologies
New York
| – | -$30K | -13 | Closed |
|
|
TAM
61
Telluride Asset Management
Wayzata,
Minnesota
| – | -$22K | -9 | Closed |
|
62
Two Sigma Investments
New York
| – | -$19K | -8 | Closed |
|
63
California Public Employees Retirement System
Sacramento,
California
| – | -$16K | -7 | Closed |
|
ONCT Hedge Fund Activity: Q1 2014 in Review
55 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2014, worth a combined $10M — down 13% from $11.5M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ONCT and 6 opened new positions — a net loss of 2 holders — while 18 trimmed existing stakes and 16 added.
The largest buyer was AQR Capital Management, adding an estimated $351K. The largest seller was TFS Capital, exiting entirely with an estimated $805K sold.
- 55 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2014, down from 58 in Q4 2013.
- Funds reported $10M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2014, down 13% quarter-over-quarter.
- 6 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2014 and 8 closed out, a net change of -2 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2014 was AQR Capital Management, an estimated $351K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2014 was TFS Capital, an estimated $805K sold.
Based on aggregated 13F filings for Q1 2014.